EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomized placebo-controlled study



Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomized placebo-controlled study



Indian Heart Journal 53(3): 376-376




(PDF emailed within 1 workday: $29.90)

Accession: 046825822

Download citation: RISBibTeXText

PMID: 11516048



Related references

Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomised, placebo-controlled trial. Lancet 356(9247): 2037-2044, 2001

Treatment effects of eptifibatide in planned coronary stent implantation in patients with chronic kidney disease (ESPRIT trial). American Journal of Cardiology 91(1): 17-21, 2003

Treatment effects of eptifibatide in planned coronary stent implantation in patients with chronic kidney disease (ESPRIT Trial). American Journal of Cardiology 91(1): 17-21, 2002

Design and methodology of the ESPRIT trial: evaluating a novel dosing regimen of eptifibatide in percutaneous coronary intervention. American Heart Journal 140(6): 834-839, 2000

Effect of Eptifibatide on coronary flow reserve following coronary stent implantation (An ESPRIT substudy). American Journal of Cardiology 87(11): 1293-1295, 2001

Platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention: The ESPRIT trial: A randomized controlled trial. JAMA (Journal of the American Medical Association) 285(19): 2468-2473, May 16, 2001

Eptifibatide in coronary stent implantation Long-term results of the ESPRIT trial. Circulation 104(17 Supplement): II 94, October 23, 2001

High-dose eptifibatide in elective coronary stent implantation Results of the ESPRIT trial. European Heart Journal 21(Abstract Supplement): 146, August-September, 2000

High-dose eptifibatide in coronary stent implantation 1 Year results of the ESPRIT trial. Journal of the American College of Cardiology 37(2 Supplement A): 76A, February, 2001

High-dose eptifibatide in coronary stent implantation 6 Month results of the ESPRIT trial. Circulation 102(18 Supplement): II 663, October 31, 2000

Effect of eptifibatide on coronary flow reserve following coronary stent implantation (an ESPRIT substudy). Enhanced Suppression of the Platelet IIb/IIIa Receptor with Integrilin Therapy. American Journal of Cardiology 87(11): 1293-1295, 2001

In-hospital costs of coronary stent implantation with and without eptifibatide (the ESPRIT Trial). Enhanced Suppression of the Platelet IIb/IIIa Receptor with Integrilin. American Journal of Cardiology 89(1): 61-64, 2002

Platelet glycoprotein IIb/IIIa blockade with eptifibatide in angioplasty followed by stent implantation at 6 month in the ESPRIT study. Italian Heart Journal. Supplement 2(9): 1029-1030, 2001

Treatment effect at different levels of creatinine clearance following eptifibatide in planned coronary stent implantation. Journal of the American College of Cardiology 37(2 Supplement A): 11A, February, 2001